Long-Term Safety and Antihypertensive Effects of Renal Denervation: Current Insights

References

• Beaney T, Schutte AE, Tomaszewski M, et al. May measurement month 2017: an analysis of blood pressure screening results worldwide. Lancet Glob Health. 2018;6(7):e736–e743. doi:10.1016/S2214-109X(18)30259-6
   PubMed Web of Science ®Google Scholar
• Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–1913.
   PubMed Web of Science ®Google Scholar
• Muntner P, Hardy ST, Fine LJ, et al. Trends in blood pressure control among US adults with hypertension, 1999–2000 to 2017–2018. JAMA. 2020;324(12):1190–1200. doi:10.1001/jama.2020.14545
   PubMed Web of Science ®Google Scholar
• Augustin A, Coutts L, Zanisi L, et al. Impact of therapeutic inertia on long-term blood pressure control: a Monte Carlo Simulation Study. Hypertension. 2021;77:1350–1359. doi:10.1161/HYPERTENSIONAHA.120.15866
   PubMed Web of Science ®Google Scholar
• Chang TE, Ritchey MD, Park S, et al. National rates of nonadherence to antihypertensive medications among insured adults with hypertension, 2015. Hypertension. 2019;74(6):1324–1332. doi:10.1161/HYPERTENSIONAHA.119.13616
   PubMed Web of Science ®Google Scholar
• Singh RR, Denton KM. Renal denervation. Hypertension. 2018;72(3):528–536. doi:10.1161/HYPERTENSIONAHA.118.10265
   PubMed Web of Science ®Google Scholar
• Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–967. doi:10.1016/S0140-6736(15)01225-8
   PubMed Web of Science ®Google Scholar
• Medtronic. Symplicity Spyral renal denervation system. Medtronic; n.d. Available from: https://europe.medtronic.com/xd-en/healthcare-professionals/products/cardiovascular/renal-denervation/symplicity.html. Accessed February 14, 2023.
   Google Scholar
• Patients. ReCor; n.d. Available from: https://www.recormedical.com/our-technology/. Accessed February 14, 2023.
   Google Scholar
• Fischell TA, Ebner A, Gallo S, et al. Transcatheter alcohol-mediated perivascular renal denervation with the peregrine system: first-in-human experience. J Am Coll Cardiol Intv. 2016;9(6):589–598. doi:10.1016/j.jcin.2015.11.041
   Google Scholar
• Reyes KRL, Bilgili G, Rader F. Team approaches to hypertension management: new opportunities for Interventionalists. Cardiac Interventions Today; 2023. Available from: https://citoday.com/articles/2023-may-june/team-approaches-to-hypertension-management-new-opportunities-for-interventionalists-1. Accessed September 2, 2023.
   Google Scholar
• Phelps J, Fink G. Abstract 289: effect of central sympatholytic treatment on the anti-hypertensive response of renal denervation in the spontaneously hypertensive rat. Hypertension. 2013;62(suppl_1). doi:10.1161/hyp.62.suppl_1.a289
   Google Scholar
• Krum H, Schlaich MP, Sobotka PA, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383(9917):622–629. doi:10.1016/S0140-6736(13)62192-3
   PubMed Web of Science ®Google Scholar
• Renal sympathetic denervation for treatment of drug-resistant; n.d. Available from: 10.1161/circulationaha.112.130880. Accessed February 14, 2023.
   Google Scholar
• Esler MD, Böhm M, Sievert H, et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the Symplicity HTN-2 randomized clinical trial. Eur Heart J. 2014;35(26):1752–1759. doi:10.1093/eurheartj/ehu209
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Vaduganathan M, Kandzari DE, et al; SYMPLICITY HTN-3 Steering Committee Investigators. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet. 2022;400(10361):1405–1416. PMID: 36130612. doi:10.1016/S0140-6736(22)01787-1
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Bhatt DL, Brar S, et al. Predictors of blood pressure response in the Symplicity HTN-3 trial. Eur Heart J. 2015;36(4):219–227. doi:10.1093/eurheartj/ehu441)
   PubMed Web of Science ®Google Scholar
• Bakris GL, Townsend RR, Flack JM, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the Symplicity HTN-3 trial. J Am Coll Cardiol. 2015;65(13):1314–1321. doi:10.1016/j.jacc.2015.01.037
   PubMed Web of Science ®Google Scholar
• Townsend RR, Mahfoud F, Kandzari DE, et al; SPYRAL HTN-OFF MED trial investigators*. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108):2160–2170. doi:10.1016/S0140-6736(17)32281-X
   PubMed Web of Science ®Google Scholar
• Böhm M, Mahfoud F, Townsend RR, et al. Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial. Eur Heart J. 2019;40:743–751. doi:10.1093/eurheartj/ehy87125
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Böhm M, Mahfoud F, et al; SPYRAL HTN-ON MED Trial Investigators. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346–2355. doi:10.1016/S0140-6736(18)30951-6
   PubMed Web of Science ®Google Scholar
• Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet. 2022;399(10333):1401–1410. doi:10.1016/S0140-6736(22)00455-X
   PubMed Web of Science ®Google Scholar
• Mahfoud F, Böhm M, Schmieder R, et al. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the global SYMPLICITY registry. Eur Heart J. 2019;40(42):3474–3482. PMID: 30907413; PMCID: PMC6837160. doi:10.1093/eurheartj/ehz118
   PubMed Web of Science ®Google Scholar
• Azizi M, Schmieder RE, Mahfoud F, et al; RADIANCE-HTN Investigators. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335–2345. doi:10.1016/S0140-6736(18)31082-1
   PubMed Web of Science ®Google Scholar
• Azizi M, Schmieder RE, Mahfoud F, et al. Six-month results of treatment-blinded medication titration for hypertension control after randomization to endovascular ultrasound renal denervation or a sham procedure in the RADIANCE-HTN SOLO trial. Circulation. 2019;139(22):2542–2553. doi:10.1161/CIRCULATIONAHA.119.040451
   PubMed Web of Science ®Google Scholar
• Azizi M, Daemen J, Lobo MD, et al. 12-month results from the unblinded phase of the RADIANCE-HTN SOLO trial of ultrasound renal denervation. JACC Cardiovasc Interv. 2020;13(24):2922–2933. doi:10.1016/j.jcin.2020.09.054
   PubMed Web of Science ®Google Scholar
• Rader F, Kirtane AJ, Wang Y, et al. Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial. EuroIntervention. 2022;18(8):e677–e685. PMID: 35913759; PMCID: PMC10241283. doi:10.4244/EIJ-D-22-00305
   PubMed Web of Science ®Google Scholar
• Azizi M, Sanghvi K, Saxena M, et al; RADIANCE-HTN investigators. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397(10293):2476–2486. doi:10.1016/S0140-6736(21)00788-1
   PubMed Web of Science ®Google Scholar
• Azizi M, Mahfoud F, Weber MA, et al. Effects of renal denervation vs sham in resistant hypertension after medication escalation: prespecified analysis at 6 months of the RADIANCE-HTN TRIO randomized clinical trial. JAMA Cardiol. 2022;7(12):1244–1252. doi:10.1001/jamacardio.2022.3904
   PubMed Web of Science ®Google Scholar
• Azizi M, Saxena M, Wang Y, et al. Endovascular ultrasound renal denervation to treat hypertension: the RADIANCE II randomized clinical trial. JAMA. 2023;329(8):651–661. doi:10.1001/jama.2023.0713
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. RADIANCE Continued Access Protocol (RADIANCE CAP). Available from: https://clinicaltrials.gov/ct2/show/NCT05017935. Accessed September 2, 2023.
   Google Scholar
• Kirtane AJ, Sharp ASP, Mahfoud F, et al. Patient-level pooled analysis of ultrasound renal denervation in the sham-controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO trials. JAMA Cardiol. 2023;8(5):464–473. doi:10.1001/jamacardio.2023.0338
   PubMed Web of Science ®Google Scholar
• Ott C, Mahfoud F, Schmid A, et al. Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension. J Hypertens. 2015;33(6):1261–1266. doi:10.1097/HJH.0000000000000556
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Renal Denervation in Chronic Kidney Disease - RDN-CKD Study (RDN-CKD). Available from: https://classic.clinicaltrials.gov/ct2/show/study/NCT04264403. Accessed September 2, 2023.
   Google Scholar
• Templin C, Jaguszewski M, Ghadri JR, et al. Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre- and post-procedural comparison with the Symplicity catheter system and the EnligHTN multi-electrode renal denervation catheter. Eur Heart J. 2013;34:2141–2148. doi:10.1093/eurheartj/eht141
   PubMed Web of Science ®Google Scholar
• Singh RR, McArdle ZM, Iudica M, et al. Sustained decrease in blood pressure and reduced anatomical and functional reinnervation of renal nerves in hypertensive sheep 30 months after catheter-based renal denervation. Hypertension. 2019;73(3):718–727. doi:10.1161/HYPERTENSIONAHA.118.12250
   PubMed Web of Science ®Google Scholar
• Sharp ASP, Tunev S, Schlaich M, et al. Histological evidence supporting the durability of successful radiofrequency renal denervation in a normotensive porcine model. J Hypertens. 2022;40(10):2068–2075. doi:10.1097/HJH.0000000000003236
   PubMed Web of Science ®Google Scholar
• Radiance-HTN trio: renal denervation effective, safe in treatment-resistant HTN. American College of Cardiology; 2021. Available from: https://www.acc.org/latest-in-cardiology/articles/2021/05/12/19/08/sun-1045am-radiance-htn-trio-acc-2021. Accessed March 17, 2023.
   Google Scholar